Biotech doubles financing in quest to silence genes behind neurological diseases

Biotech doubles financing in quest to silence genes behind neurological diseases

Aerska Therapeutics, based in Dublin and London, is focused on using ‘brain shuttles’ to deliver molecules past blood-brain barrier.

Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain - European Biotechnology Magazine

Aerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025. The post Dublin-based Aerska secures $39M Series A to push RNA medicines into the br…